Natco Pharma has launched Bosentan tablets for oral suspension, 32mg, a generic version of Actelion Pharmaceuticals’ Tracleer in the U.S. It holds the first-to-file status for this product and will have 180-day generic drug exclusivity, Natco said on Wednesday (August 20, 2025. Lupin is its marketing partner for the product. Bosentan TFOS, 32mg, had estimated […]
Continue Reading
According to Natco Pharma, during the April-June quarter this year, the business faced pricing pressure in the U.S. product portfolio and the company incurred increased R&D expenses on account of high value projects. File | Photo Credit: Reuters Generic drugmaker Natco Pharma reported consolidated net profit for the June quarter declined more than 28% to […]
Continue Reading
Natco Pharma has made an offer to acquire nearly 36% stake in South African pharmaceutical company Adcock Ingram Holdings (AIHL) for $226 million (around ₹2,000 crore). The proposal to acquire the stake from minority shareholders in an all cash deal is a strategic investment aimed at to expanding geographic footprint in South Africa, Natco said […]
Continue Reading
A bottle of Revlimid seen at a store in Utah. File photo | Photo Credit: Reuters Natco Pharma has launched its generic version of Celgene Corporation’s cancer drug Revlimid (lenalidomide capsules) in additional strengths in the United States. The 2.5 mg and 20 mg strengths of the prescription medicine used in adults for the treatment […]
Continue Reading
The promoter and promoter group’s stake, in the event of the maximum buyback, will increase from 48.82% to 49.63%. | Photo Credit: AP Natco Pharma has got the board approval for a ₹210 crore share-buyback proposal. The company said under the proposal it will take the open market route to buy back upto 30 lakh […]
Continue ReadingCopyright © 2022
Designed and Developed by Cpool Digital Learning
